Part D Plans Need More Leverage Over Specialty Drugs, CMS Official Says
This article was originally published in The Pink Sheet Daily
CMS Center for Medicare Director Sean Cavanaugh says controlling Medicare drug spending “will be a top priority in the coming years” for the agency.
You may also be interested in...
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
What's in – and what fell out of – the massive US stimulus package.